JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

31.6 -0.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

31.53

Max

32.37

Põhinäitajad
By Trading Economics
Sissetulek	-28M 22M
Müük	4.3M 244M
P/E Sektori keskmine	10.897 60.328
Kasumimarginaal	9.224
Töötajad	293
EBITDA	-22M 52M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+34.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	161M 1.7B
Eelmine avamishind	32.07
Eelmine sulgemishind	31.6

Uudiste sentiment

By Acuity

50%

178 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23. apr 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23. apr 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23. apr 2026, 22:33 UTC

Tulu

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23. apr 2026, 22:17 UTC

Tulu

PLS Executed Offtake Agreement With Ronbay

23. apr 2026, 22:17 UTC

Tulu

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23. apr 2026, 22:16 UTC

Tulu

PLS Commences Commissioning of Midstream Demonstration Plant

23. apr 2026, 22:15 UTC

Tulu

PLS Group Reaffirms FY26 Guidance for All Metrics

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23. apr 2026, 22:13 UTC

Tulu

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23. apr 2026, 22:12 UTC

Tulu

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23. apr 2026, 22:12 UTC

Tulu

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23. apr 2026, 22:11 UTC

Tulu

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23. apr 2026, 22:10 UTC

Tulu

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23. apr 2026, 22:09 UTC

Tulu

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23. apr 2026, 22:08 UTC

Tulu

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23. apr 2026, 22:04 UTC

Tulu

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23. apr 2026, 21:56 UTC

Market Talk

Tulu

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23. apr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23. apr 2026, 21:27 UTC

Tulu

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23. apr 2026, 21:25 UTC

Tulu

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23. apr 2026, 21:24 UTC

Tulu

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23. apr 2026, 21:24 UTC

Tulu

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23. apr 2026, 21:21 UTC

Tulu

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23. apr 2026, 21:21 UTC

Tulu

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

34.16% tõus

12 kuu keskmine prognoos

Keskmine 42.89 USD 34.16%

Kõrge 72 USD

Madal 25 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

178 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.